<qe class="nuyqr"></qe>

z6尊龙时凯

Be the most trusted biotech company

2020-03-31

Henlius Novel Anti-EGFR Monoclonal Antibody Demonstrated Favorable Safety and Tolerability Profile in Its Phase 1 Clinical Study
2020-03-23

Open Your Mind, Unleash Your Potential | Exclusive Interview of Henlius Senior Vice President of Technical Operations, Dr. Simon Hsu
2020-03-11

First Patient Dosed in Phase 2 Clinical Trial of Henlius Anti-PD-1 mAb in Combination with Chemotherapy in Patients with Advanced Cervical Cancer
2020-03-09

Henlius Received Acceptance Notification for Clinical Trial Application from NMPA for its Denosumab Biosimilar HLX14
2020-03-04

First Patient Dosed in Phase 1 Study of Henlius Innovative Anti-c-MET Monoclonal Antibody HLX55 for the Treatment of Advanced Solid Tumours
2020-02-19

Henlius Appointed Mr. Wenjie Zhang as President of the Company, Moving Towards a New Phase of Overall Commercial Operation
2020-02-18

Henlius Successfully Held Its Fourth Scientific Advisory Board (SAB) Meeting
2020-01-21

Henlius Anti-HER2 Domain II Monoclonal Antibody HLX11 Received Clinical Approval from NMPA
2020-01-10

Henlius Anti-CTLA-4 Monoclonal Antibody HLX13 Received IND Application Acceptance Notification from NMPA

1
2
3
4